Creative Biolabs has extensive experience in the field of immuno-oncology, our in-house experts specialize in the full spectrum of immuno oncology (IO) research and have the capability to provide comprehensive NY-ESO-1 assay portfolio services.
NY-ESO-1 (New York esophageal squamous cell carcinoma 1), as a member of the cancer-testis antigen (CTA) family, is an 18-kDa protein with 180 amino acids presenting a glycine-rich N-terminal region and an extremely hydrophobic C-terminal region with a Pcc-1 domain.
NY-ESO-1 expression has been found in a variety range of tumor types, including metastatic melanoma, breast cancer, ovarian cancer, neuroblastoma, myeloma, bladder cancer, synovial sarcoma, esophageal cancer, hepatocellular cancer, head and neck cancer, non-small cell lung cancer and prostate cancer. Meanwhile, NY-ESO-1 expression could be considered as a prognostic biomarker, which expression is associated with poor clinical outcomes in some cancers.
NY-ESO-1 is widely considered to be a good candidate target for immunotherapy, because its restricted expression profile in healthy adult tissues effectively reduces the risk of off-target toxicity. To date, NY-ESO-1 targeted therapies have come a long way, targeting the antigen using a series of approaches from peptide and protein vaccinations, antibodies, adoptive T cell therapies to combinational treatment modalities. There have been some promising results, driving new clinical trials in many types of cancers.
Fig.1 NY-ESO-1 targeted approaches for cancer immunotherapy. (Thomas, 2018)
Creative Biolabs has robustly developed in vitro and in vivo platforms to provide reproducible NY-ESO-1 targeted assays for our clients all over the world. We are dedicated to designing comprehensive research practices and handling high-quality studies to support your biopharmaceutical development pipeline.
For further details, please don't hesitate to contact us for more information.
Reference
For Research Use Only | Not For Clinical Use
Download our brochure